Genenta Science (NASDAQ:GNTA) Stock, Quote.Headers.trade-ideas

Genenta Science

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADSK

AGIL

ANGH

ATGL

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATPC

CNTB

EDSA

GHRS

GNTA

GSX Techedu Inc. American Depositary Shares

GOTU

GYRE

HSCS

MIRA

PXMD

RVYL

SHOT

SPRC

TCON

THAR

URBN

Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.

Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

AKTX

ALLG

ANPC

ANVS

APGN

AREB

ARQQ

ASAN

AUUD

AYLA

BBIG

CDLX

CDRO

CLAQ

CLVS

CVNA

DICE

EVEX

GSHD

HYPR

IBRX

IDAI

IDYA

IMTX

INLX

KSPN

LCID

LPTX

LSAK

MEGL

MOGU

NRBO

NTCT

NUWE

PIXY

PYPD

RBBN

REBN

RGLS

RMED

RYTM

SGML

STRC

SWTX

TRDA

TUEM

VTNR

VTYX

WETG

YOSH

Gainers


	NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.


Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday

AZRE

SHPH

SPPI

Gainers


	Ventyx Biosciences, Inc.  (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.


Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday&#39;s Mid-Day Session

Genenta Science S.p.A. - American Depositary Shares

Genenta Science SPA

<p>Needham  analyst Charles Shi   downgrades ACM Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) from Buy to Hold and maintains the price target from $25 to $25.</p>


Downgrades

Price Target

Analyst Ratings

ACMR

Needham Downgrades ACM Research to Hold, Maintains Price Target to $25

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index For November 50.8 Vs. 50.0 Est.; 52.0 Prior

U.K. Composite Purchasing Managers' Index For November 50.5 Vs. 49.9 Est.; 51.8 Prior

<p>On Tuesday, <strong>Jeff Bezos&#8217; Amazon.com, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a href="https://www.benzinga.com/24/12/42301222/amazon-stock-moves-higher-as-aws-unveils-new-ai-advancements-what-you-need-to-know">unveiled advanced AI chip</a> clusters designed to enhance the performance of its partner, <strong>Anthropic</strong>.</p>
<p>This development aims to challenge the current market leaders, <strong>Nvidia Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and <strong>ChatGPT</strong>-maker <strong>OpenAI</strong>.</p>
<p><strong>What Happened:</strong> During Amazon's biggest re:Invent conference of the year, the tech giant deployed hundreds of thousands of its <strong>Trainium2 </strong>semiconductors into clusters, significantly boosting Anthropic&#8217;s processing power.</p>
<p>The new chip cluster, named <strong>Project Rainier</strong>, is expected to be the world&#8217;s largest dedicated AI hardware set, containing over 100,000 chips.</p>
<p>Amazon intends to provide an alternative to Nvidia&#8217;s GPUs, which are often expensive and scarce. The company said it will provide customers with computing power supported by Nvidia's new <strong>Blackwell</strong> chip beginning early next year, <a href="https://www.bloomberg.com/news/articles/2024-12-03/amazon-unveils-chip-clusters-with-five-times-power-for-anthropic">reported</a> Bloomberg.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/24/12/42286671/apples-foldable-iphone-could-spark-smartphone-market-revival-in-2026-says-expert?itm_source=parsely-api">Apple&#8217;s Foldable iPhone Could Spark Smartphone Market Revival In 2026, Says Expert</a></strong></p>
<p>Amazon Web Services announced that it began providing customers with its latest chips starting Tuesday.</p>
<p>Amazon&#8217;s CEO, <strong>Andy Jassy</strong>, introduced the <strong>Nova</strong> models, which can generate text, images, and video. These models are Amazon&#8217;s latest attempt to rival OpenAI&#8217;s advanced GPT models.&nbsp;</p>
<p><strong>Why It Matters: </strong>This latest development in AI chip clusters is part of Amazon's ongoing partnership with Anthropic. The e-commerce giant has boosted this collaboration with a $4 billion investment in the AI startup, bringing the <a href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch">total to $8 billion</a>.</p>
<p>This partnership also positions AWS as Anthropic&#8217;s primary cloud provider and training partner, leveraging <strong>AWS Trainium</strong> and <strong>Inferentia</strong> chips for future models.</p>
<p>Earlier in September, Amazon also received some positive news when the U.K.&#8217;s Competition and Markets Authority approved this partnership, allowing Amazon to proceed <a href="https://www.benzinga.com/m-a/24/09/41067395/amazons-partnership-with-jeff-bezos-backed-anthropic-gets-green-signal-from-uk-competition-watchdog">without regulatory hurdles</a>.</p>
<p><em>Subscribe to the </em><a href="https://bztechtrends.beehiiv.com/subscribe"><em>Benzinga Tech Trends newsletter</em></a><em> to get all the latest tech developments delivered to your inbox.</em></p>
<p>Last month, Amazon reported <a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">third-quarter sales</a> of $158.9 billion, reflecting an 11% increase compared to the last year. This figure surpassed the Wall Street consensus estimate of $157.2 billion, according to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">data from Benzinga Pro</a>.</p>
<p><strong>Price Action: </strong>Amazon&#8217;s stock rose by 1.30% on Tuesday, finishing at $213.44. In pre-market trading, it saw a further increase of 0.35%, reaching $214.18. So far this year, Amazon shares have surged by 43.76%, significantly outperforming the Nasdaq 100 index, which gained 28.32% over the same period.</p>
<p>Amazon holds a consensus price target of $238.16 from 38 analysts, with the highest target of $285 set by JMP Securities on Nov. 1. The latest ratings from BMO Capital, MoffettNathanson, and Redburn Atlantic point to an average target of $239.67, suggesting an 11.92% upside.</p>
<p><figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AMZN/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04045012/Screenshot-2024-12-04-at-3.20.05%E2%80%AFPM-1024x380.png" alt="" class="wp-image-676046" /></a></figure></p>
<p><em>Check out more of Benzinga's Consumer Tech coverage by </em><a href="https://www.benzinga.com/topic/consumer-tech"><em>following this link</em></a><em>.</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42253989/benzinga-bulls-and-bears-amazon-tesla-rivian-palantir-and-how-dogecoin-helped-low-income-families-achieve-homeownership">Benzinga Bulls And Bears: Amazon, Tesla, Rivian, Palantir And How Dogecoin Helped Low-Income Families Achieve Homeownership</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>


Equities

Tech

Media

AMZN

NVDA

Jeff Bezos' Amazon Unveils Powerful AI Chip Clusters To Supercharge Anthropic's Models, Challenging Nvidia And OpenAI's Dominance

Eurozone Services Purchasing Managers Index For November 49.5 Vs. 49.2 Est.; 51.6 Prior

HCOB Eurozone Composite Purchasing Managers Index For November 48.3 Vs. 48.1 Est.; 50.0 Prior

France Services Purchasing Managers Index For November 46.9 Vs. 45.7 Est.; 49.2 Prior

CME Group Announced It Will Provide CME Term €STR Reference Rates To Meet Client Demand For A Term Rate Anchored In €STR Markets

<p>Mizuho  analyst Steven Valiquette   initiates coverage on Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Neutral rating and announces Price Target of $21.</p>


Initiation

XRAY

Mizuho Initiates Coverage On Dentsply Sirona with Neutral Rating, Announces Price Target of $21

Germany Services Purchasing Managers Index For November 49.3 Vs. 49.4 Est.; 51.6 Prior

<p>Mizuho  analyst Steven Valiquette   initiates coverage on Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Neutral rating and announces Price Target of $75.</p>


HSIC

Mizuho Initiates Coverage On Henry Schein with Neutral Rating, Announces Price Target of $75

NSPR

CORRECTION: InspireMD Q1Numbers Are Old And Were Published Erroneously; Now Deleted

<p>JMP Securities  analyst Jason Butler   initiates coverage on Abivax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) with a Market Outperform rating and announces Price Target of $33.</p>


ABVX

JMP Securities Initiates Coverage On Abivax with Market Outperform Rating, Announces Price Target of $33

<p>Mizuho  analyst Steven Valiquette   initiates coverage on Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral rating and announces Price Target of $70.</p>


SOLV

Mizuho Initiates Coverage On Solventum with Neutral Rating, Announces Price Target of $70

<p>Mizuho  analyst Steven Valiquette   initiates coverage on Talkspace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>) with a Outperform rating and announces Price Target of $5.</p>


TALK

Mizuho Initiates Coverage On Talkspace with Outperform Rating, Announces Price Target of $5

<p>Ascendiant Capital  analyst Edward Woo   maintains Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) with a Buy and lowers the price target from $14 to $11.</p>


INTZ

Ascendiant Capital Maintains Buy on Intrusion, Lowers Price Target to $11

<p>Mizuho  analyst Steven Valiquette   initiates coverage on Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) with a Underperform rating and announces Price Target of $20.</p>


NVST

Mizuho Initiates Coverage On Envista Holdings with Underperform Rating, Announces Price Target of $20

<p>Oppenheimer  analyst Jay Olson   maintains Terns Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) with a Outperform and raises the price target from $17 to $20.</p>


TERN

Oppenheimer Maintains Outperform on Terns Pharma, Raises Price Target to $20

NATL

NCR Atleos Announced That East Of England Co-op Has Extended Its Relationship With Atleos To Provide ATMs Through The Cashzone Network Across Its Stores

<p>Evercore ISI Group  analyst Thomas Gallagher   maintains Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) with a Underperform and lowers the price target from $104 to $102.</p>


Evercore ISI Group Maintains Underperform on Aflac, Lowers Price Target to $102

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, an Italian biotech firm, has entered into an agreement with V...

Genenta Science Announces ADS Sales Agreement

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, a biotech company based in Milan, is focused on the research,...

Genenta Science Advances Biotech Endeavors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cingulate Inc (CING – Research Report) and Genenta...

Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;</p>



<p>Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.</p>



<p>Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.</p>



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p><strong>FibroGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fgen-stock-quote/"><strong>FGEN</strong></a></span>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.</p>



<p>Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;</p>



<p>One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.</p>



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Nuvectis Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvct-stock-quote/"><strong>NVCT</strong></a></span>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.</p>



<p>Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;</p>



<p>The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.</p>



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Relmada Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/"><strong>RLMD</strong></a></span>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.</p>



<p>REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.</p>



<p>The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;</p>



<p>Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.</p>



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div><p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;</p>



<p>The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;</p>



<p>The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.</p>



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div><p>Let&rsquo;s begin discussing<strong> Genenta Science</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnta-stock-quote/"><strong>GNTA</strong></a></span>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.</p>



<p>While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.</p>



<p>The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;</p>



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div><p><strong>Affimed</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/afmd-stock-quote/"><strong>AFMD</strong></a></span>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.</p>



<p>The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.</p>



<p>AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;</p>



<p>As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;</p>



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.</p>



<p>As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.</p>



<p>However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;</p>



<p>What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.</p>



<p><em><strong>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks</strong>: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More</strong>: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a></em></p>



<p><em>On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines.</em></a></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Penny Biotech Stocks to Triple Your Investment

Maxim Group analyst Jason McCarthy maintained a Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report) yesterday and set a price ...

Buy Rating Affirmed for Genenta Science Amid Promising Developments in Gene Therapy Trials

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR – Research Report) and Genenta Science SpA Sponsored...

Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Genenta Science SpA Sponsored ADR (GNTA)

09:35 EDT Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Genenta Science SPA (ADR) trading resumes

Genenta Science (GNTA) announced that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Str...

Genenta Science CEO to present at U.S. Senate meeting

09:40 EST Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

09:30 EST Genenta Science (GNTA) SPA (ADR) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ...

Genenta Science SPA (ADR) trading halted, volatility trading pause

AFMD

ANIX

CING

FGEN

LPCN

NVCT

RLMD

Health Care

Press Releases

General

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Management

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

Comments

Genenta Science

Genenta Science (GNTA) Forecast

Genenta Science (NASDAQ:GNTA) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga